Evidence map›Paper›PMID 36304135›Full record

ArticleOpen medicine (Warsaw, Poland)2022

circ-LIMK1 regulates cisplatin resistance in lung adenocarcinoma by targeting miR-512-5p/HMGA1 axis.

Ya Li, Fangfang Li, Yaya Wang, Fangyu Song, Lin Qi, Qiang Hu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open medicine (Warsaw, Poland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ya LiDepartment of Respiratory and Critical Care Medicine, Xi'an Gaoling District Hospital, Xi'an, China.
Fangfang LiDepartment of Respiratory and Critical Care Medicine, Xi'an Gaoling District Hospital, Xi'an, China.
Yaya WangDepartment of Respiratory and Critical Care Medicine, Xi'an Gaoling District Hospital, Xi'an, China.
Fangyu SongDepartment of Respiratory and Critical Care Medicine, Xi'an Gaoling District Hospital, Xi'an, China.
Lin QiDepartment of Respiratory and Critical Care Medicine, Xi'an Gaoling District Hospital, Xi'an, China.
Qiang HuDepartment of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Xi'an Medical College, No. 277 Youyi West Road, Beilin District, Xi'an 710068, China.
First Hospital of Xi'an · CNXi'an Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to unveil the detailed role and new mechanism of circ-LIMK1 in lung adenocarcinoma. Real-time quantitative polymerase chain reaction was performed to analyze the expression of circ-LIMK1, miR-512-5p, and HMGA1. 3-(4,5)-Dimethylthiahiazo(-

Indexed as

circ-LIMK1cisplatinHMGA1lung adenocarcinomamiR-512-5p

Identifiers

PMID36304135
PMCPMC9547352
OpenAlexW4307582204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.